Michael Cardamone

High Street
Randwick, NSW 2031, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 36 publications

Eligibility for Thrombolysis for Pediatric Acute Ischemic Stroke.

Eligibility for Thrombolysis for Pediatric Acute Ischemic Stroke.

Journal: Stroke
Published: August 27, 2026

Corrigendum to "The efficacy and safety of ketogenic diet therapy among adolescents and adults with drug resistant epilepsy: A systematic review and meta-analysis" [Seizure: European Journal of Epilepsy volume 140 (2026) p39-51].

Corrigendum to "The efficacy and safety of ketogenic diet therapy among adolescents and adults with drug resistant epilepsy: A systematic review and meta-analysis" [Seizure: European Journal of Epilepsy volume 140 (2026) p39-51].

Journal: Seizure
Published: August 03, 2026

The efficacy and safety of ketogenic diet therapy among adolescents and adults with drug resistant epilepsy: A systematic review and meta-analysis.

The efficacy and safety of ketogenic diet therapy among adolescents and adults with drug resistant epilepsy: A systematic review and meta-analysis.

Journal: Seizure
Published: March 09, 2026

WWOX-Related Developmental and Epileptic Encephalopathy: Expanding the Clinical Spectrum and Deciphering the Genotype-Phenotype.

WWOX-Related Developmental and Epileptic Encephalopathy: Expanding the Clinical Spectrum and Deciphering the Genotype-Phenotype.

Journal: Neurology
Published: August 28, 2025

Pathogenic Variants in RNU2-2, a Non-coding Spliceosomal RNA, Cause a Distinctive Developmental and Epileptic Encephalopathy.

Pathogenic Variants in RNU2-2, a Non-coding Spliceosomal RNA, Cause a Distinctive Developmental and Epileptic Encephalopathy.

Journal: Annals of neurology
Published: May 21, 2025

Cerebrospinal fluid metabolomics in autistic regression reveals dysregulation of sphingolipids and decreased β-hydroxybutyrate.

Cerebrospinal fluid metabolomics in autistic regression reveals dysregulation of sphingolipids and decreased β-hydroxybutyrate.

Journal: EBioMedicine
Published: November 20, 2024

Clinician Understanding, Acceptance and utilization of Ketogenic diet therapy for epilepsy in Australia and New Zealand: An online survey.

Clinician Understanding, Acceptance and utilization of Ketogenic diet therapy for epilepsy in Australia and New Zealand: An online survey.

Journal: Epilepsy & behavior reports
Published: August 04, 2024

Solving the Etiology of Developmental and Epileptic Encephalopathy with Spike-Wave Activation in Sleep (D/EE-SWAS).

Solving the Etiology of Developmental and Epileptic Encephalopathy with Spike-Wave Activation in Sleep (D/EE-SWAS).

Journal: Annals of neurology
Published: February 23, 2024

Ketogenic diet modifies ribosomal protein dysregulation in KMT2D Kabuki syndrome.

Ketogenic diet modifies ribosomal protein dysregulation in KMT2D Kabuki syndrome.

Journal: EBioMedicine
Published: January 10, 2024

Ketogenic Diets in Children With Intractable Epilepsy and its Effects on Gastrointestinal Function, Gut Microbiome, Inflammation, and Quality of Life.

Ketogenic Diets in Children With Intractable Epilepsy and its Effects on Gastrointestinal Function, Gut Microbiome, Inflammation, and Quality of Life.

Journal: Journal of pediatric gastroenterology and nutrition
Published: September 08, 2023

Integration of EpiSign, facial phenotyping, and likelihood ratio interpretation of clinical abnormalities in the re-classification of an ARID1B missense variant.

Integration of EpiSign, facial phenotyping, and likelihood ratio interpretation of clinical abnormalities in the re-classification of an ARID1B missense variant.

Journal: American journal of medical genetics. Part C, Seminars in medical genetics
Published: July 13, 2023

Treatment of severe acute necrotizing encephalopathy of childhood with interleukin-6 receptor blockade in the first 24 h as add-on immunotherapy shows favorable long-term outcome at 2 years.

Treatment of severe acute necrotizing encephalopathy of childhood with interleukin-6 receptor blockade in the first 24 h as add-on immunotherapy shows favorable long-term outcome at 2 years.

Journal: Brain & development
Published: October 12, 2022
Showing 1-12 of 36

Last Updated: 09/26/2026